Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianming He

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Medicine|November 19, 2022
Efficacy of ginseng oral administration and ginseng injections on cancer-related fatigue: A meta-analysisHuijing Li, Tianwen Hou, Shijiang Sun, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2020
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III StudiesMichele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, et al.
Journal of Comparative Effectiveness Research|August 12, 2025
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myelomaJianming He, Karen Chiang, Xiwu Lin, et al.
Translational Cancer Research|May 14, 2023
Efficacy and safety of methylphenidate and ginseng in cancer-related fatigue: a network meta-analysis of randomized controlled trialsHuijing Li, Kaimeng Che, Zheng Zhi, et al.
Medicine|January 3, 2023
Network meta-analysis and cost-effectiveness analysis of infliximab, cyclosporine and tacrolimus for ulcerative colitisXueqi Wang, Qiubo Li, Shijiang Sun, et al.
Advances in Therapy|July 25, 2022
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple MyelomaJianming He, Heather Berringer, Bart Heeg, et al.
Burns & Trauma|October 18, 2023
Actin polymerization inhibition by targeting ARPC2 affects intestinal stem cell homeostasisRuzhen Zhang, Sheng Chen, Zhifan Yang, et al.
Leukemia & Lymphoma|November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparisonMaria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Ejhaem|July 18, 2022
Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligiblePieter Sonneveld, María-Victoria Mateos, Adrian Alegre, et al.
Advances in Therapy|October 17, 2020
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching AnalysisVania Hungria, Deborah M Martínez-Baños, María-Victoria Mateos, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Medicine|November 19, 2022
Efficacy of ginseng oral administration and ginseng injections on cancer-related fatigue: A meta-analysisHuijing Li, Tianwen Hou, Shijiang Sun, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2020
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III StudiesMichele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, et al.
Journal of Comparative Effectiveness Research|August 12, 2025
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myelomaJianming He, Karen Chiang, Xiwu Lin, et al.
Translational Cancer Research|May 14, 2023
Efficacy and safety of methylphenidate and ginseng in cancer-related fatigue: a network meta-analysis of randomized controlled trialsHuijing Li, Kaimeng Che, Zheng Zhi, et al.
Medicine|January 3, 2023
Network meta-analysis and cost-effectiveness analysis of infliximab, cyclosporine and tacrolimus for ulcerative colitisXueqi Wang, Qiubo Li, Shijiang Sun, et al.
Advances in Therapy|July 25, 2022
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple MyelomaJianming He, Heather Berringer, Bart Heeg, et al.
Burns & Trauma|October 18, 2023
Actin polymerization inhibition by targeting ARPC2 affects intestinal stem cell homeostasisRuzhen Zhang, Sheng Chen, Zhifan Yang, et al.
Leukemia & Lymphoma|November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparisonMaria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Ejhaem|July 18, 2022
Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligiblePieter Sonneveld, María-Victoria Mateos, Adrian Alegre, et al.
Advances in Therapy|October 17, 2020
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching AnalysisVania Hungria, Deborah M Martínez-Baños, María-Victoria Mateos, et al.
Pageof 7